Clinical pharmacology of carboplatin

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Experimental and clinical data indicate that carboplatin is as effective as cisplatin in the treatment of ovarian cancer patients with advanced bulky disease. It has an improved toxicity profile with a low incidence of ototoxicity, neuropathy, and nephropathy. In the absence of severe myelosuppression, the dose of carboplatin should be escalated in patients who have good renal function. Over the next few years, carboplatin will either replace cisplatin, or will be easier to use in a dose-intensive fashion.

Original languageEnglish (US)
Pages (from-to)6-8
Number of pages3
JournalSeminars in Oncology
Issue number4 SUPPL. 7
StatePublished - Jan 1 1990

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Clinical pharmacology of carboplatin'. Together they form a unique fingerprint.

Cite this